Metronidazole oral tablets are a prescription dosage-form family, not a single uniform medicine that every listing describes precisely. In U.S. generic labeling, standard immediate-release tablets commonly contain 250 mg or 500 mg of metronidazole per tablet. The pharmacy needs to match the tablet strength, oral route and prescribed quantity to the clinician's order. A search result for “Flagyl tablets” is not enough to identify the product or establish whether branded stock is actually marketed.
The tablet distinction matters because oral metronidazole also comes as 375 mg capsules, 750 mg extended-release tablets and an oral suspension. The 750 mg ER formulation is not simply a larger version of an ordinary 500 mg tablet; capsule and liquid packages present other differences. Read the individual 250 mg tablet and 500 mg tablet guides for their particular strengths, and use this hub for understanding the tablet dosage form.
This page focuses on product identification and prescription dispensing rather than recommending an antibiotic regimen. Only a clinician can decide which medicine and dose are appropriate for a diagnosed condition. Once that prescription exists, patients can compare legitimately dispensed products using the details on the label and the pharmacist's guidance. Our oral pharmacy access guide addresses where the purchasing process fits.
An immediate-release oral tablet is a solid dosage form with a defined milligram strength and drug-release properties. It is meant to be swallowed by mouth according to the prescription. Metronidazole gels for skin or vaginal use are different medicines for dispensing purposes even when a shopper sees the same ingredient name. The name of the active drug by itself is therefore insufficient to identify what should be supplied.
A bottle label should let the pharmacist and patient verify ingredient, oral route, dosage form, tablet strength and prescribed instructions. Additional details such as manufacturer, imprint and quantity help distinguish packages. FDA labeling is useful for checking the product identity but does not confirm that any particular manufacturer or strength is stocked today.
| Listing | Dosage form | Main check | Do not assume |
|---|---|---|---|
| Metronidazole 250 mg | Immediate-release oral tablet | 250 mg per tablet | Same instructions as a 500 mg order |
| Metronidazole 500 mg | Immediate-release oral tablet | 500 mg per tablet | Same product as vaginal gel |
| Metronidazole 375 mg | Oral capsule family | Capsule, not ordinary tablet | Equivalent capsule-to-tablet change |
| Metronidazole ER 750 mg | Extended-release oral tablet | ER designation and special directions | Ordinary immediate-release mechanism |
| LIKMEZ 500 mg/5 mL | Oral suspension | Drug amount per measured liquid volume | One-to-one equivalence with a tablet |
Metronidazole 250 mg is one of the established U.S. immediate-release tablet strengths. It identifies the amount in each tablet, not the amount any individual needs for an infection. Brand history, package size and generic labeler can affect how it appears in pharmacy systems. The 250 mg label should not be confused with a liquid concentration or with a prescribed total daily dose.
A prescription for 250 mg tablets should be interpreted and dispensed using its own instructions and quantity. If the requested package is unavailable, the pharmacist can discuss possible options with the prescriber as required. See the 250 mg tablet product profile for targeted checks without repeating the broader tablet framework here.
A 500 mg immediate-release tablet is another common oral presentation. In the U.S. it may be supplied as an FDA-approved generic tablet under different labelers, but identifying the ingredient and strength does not establish suitability for any diagnosis. A 500 mg oral tablet has a systemic route and must not be confused with the concentration of a vaginal or skin product.
The label notation on a liquid product such as 500 mg/5 mL also has a different meaning. It describes an amount per liquid volume, not a tablet. The 500 mg tablet guide concentrates on matching that strength to a written oral prescription.
The FDA has placed branded FLAGYL tablets in the 250 mg and 500 mg strengths in the discontinued section of the Orange Book and determined their withdrawal was not for reasons of safety or effectiveness. That is an important regulatory distinction: the brand's marketing history should not be confused with the status of approved generic tablet products referencing it.
A search listing may use Flagyl as a familiar synonym for metronidazole. It does not prove that the specific branded tablet can be purchased. Confirm the offered active ingredient and labeled form and, where a brand matters to the prescription, ask the pharmacist to explain the actual product identity. The Flagyl overview covers its wider brand story.
The 250 mg and 500 mg tablet family is ordinarily immediate release, while a 750 mg extended-release tablet uses an altered release design and has distinct labeled administration requirements. Release type is part of the product, not merely a dosing preference. Splitting a modified-release tablet or exchanging it for several immediate-release tablets without professional authorization can change the intended delivery.
Patients should check that a prescription and pharmacy listing agree on immediate-release or ER status before comparing strengths. For the specific 750 mg product, the extended-release page addresses its product status, administration rules and historical Flagyl ER context.
Manufacturer or labeler names, tablet imprints and NDC package identifiers can help a pharmacist verify which approved product was dispensed. Different approved generic tablets may have different appearances or package configurations. An NDC refers to a particular product/package representation; it is not a clinical indication or a warranty of supply, efficacy for a new condition or availability at every pharmacy.
If an oral tablet looks different from a past refill, do not rely on color alone. Compare the prescription label, ask the pharmacist to identify the imprint and manufacturer, and check that the strength and form remain correct. Product-authenticity concerns should be addressed through the dispensing pharmacy and appropriate regulators.
A valid U.S. prescription should clearly indicate the drug, form, route, strength, directions and quantity. A pharmacist evaluates the order and may need to contact the prescriber if the dosage form or strength is ambiguous. An online price listing, a saved screenshot or a historical prescription is not a substitute for that process.
Patients can check that the final container says oral tablets in the prescribed strength and that the directions are understood. A pharmacy may be able to explain authorized generic substitution, but patients should not change between 250 mg and 500 mg tablets or between tablets and capsules on their own. The prescription requirements page explains this handoff.
Oral metronidazole has meaningful interaction, allergy and adverse-effect considerations. The label addresses hypersensitivity, neurological symptoms, certain medication interactions and antibiotic stewardship. The clinician must consider relevant history, including liver disease, pregnancy and concomitant therapies, and a pharmacist can help patients understand the actual product-specific instructions.
A tablet being available as a generic does not eliminate medical risks. If significant symptoms occur or instructions are unclear, seek medical advice promptly rather than experimenting with tablet strengths. The appropriate prescription is tied to a diagnosed problem and should not be reused for an unrelated future infection.
A pharmacy search result might display “metronidazole tablets” in a summary while the detailed record refers to 500 mg rather than the prescribed 250 mg. Another result may contain “Flagyl” as a searchable synonym without providing a marketed branded tablet. A third may place an extended-release product in the same search category as ordinary tablets. Each case illustrates why sorting by drug name alone is insufficient for safe product selection.
Before requesting a fill, inspect the full medicine description and have a pharmacist resolve mismatches. A meaningful product match should include oral route, strength, formulation, prescription quantity and any brand-specific instruction. Search filters, manufacturer imagery and price snippets are convenient aids at best; they are not substitutes for a reviewed order and an actual dispensing label.
Verify that the drug name, oral tablet route, 250 mg or 500 mg strength, immediate-release status, prescribed quantity and directions all match what the clinician ordered. Confirm whether the pharmacy is dispensing a generic and whether any brand preference was recorded. When a difference exists, ask the pharmacist to explain it before use.
If stock is the limiting issue, separate availability discussions from medical substitution decisions. A pharmacy can check which specific product is obtainable and whether a different approved equivalent could be supplied under applicable rules. For that separate process, see metronidazole availability checks.
Common U.S. immediate-release oral tablet strengths include 250 mg and 500 mg. Extended-release tablets are a distinct product family and should be verified separately.
They differ in strength. A change in tablet strength or count must follow the clinician’s instructions and pharmacy rules rather than a patient’s own calculation.
Oral tablets and vaginal gel are different labeled dosage forms and routes. A clinician must determine which is appropriate for the diagnosis; they should not be substituted based on ingredient alone.
Capsules and tablets are different dosage forms. The 375 mg metronidazole capsule product family is not the same prescription item as a 250 mg or 500 mg tablet.
No. The 750 mg extended-release product has a modified release profile and separate instructions; it is not simply an immediate-release tablet with more ingredient.
The branded FLAGYL 250 mg and 500 mg tablet products are on the FDA discontinued product list. Ask a pharmacist about the exact prescribed product rather than assuming a branded item is stocked.
Approved generics can differ in imprint, color and packaging. The dispensing pharmacy can check the manufacturer, strength and label information to confirm the medicine.
No. An NDC identifies a labeled product/package, not live inventory. The pharmacy must confirm actual supply.
Yes. Oral metronidazole tablets are prescription medicines in the United States, and appropriate clinical assessment comes before pharmacy dispensing.
Do not change how a tablet is taken without checking the exact product instructions with a pharmacist or prescriber. Extended-release tablets have particularly important restrictions.